Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr

Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants

India reiterates commitment to adolescents on launch of ‘Economic Case for Investment in the Well-being of Adolescents in India’ report

Report highlights significant improvements in adolescent well-being in India

Merck Life Science inks MoU with ICAR-CIFT, Kochi for research in fishing process

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis

Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr

Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024

USFDA inspects Gland Pharma’s Dundigal facility

The inspection was concluded with two 483 observations

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)